Canopus Biopharma Inc. (CBIA)
Market Closed
23 Jul, 20:00
OTC PINK OTC PINK Primary $
0. 00
0
0%
$
455.07K Market Cap
- P/E Ratio
0% Div Yield
0 Volume
- Eps
$ 0
Previous Close Day Range
0 0
Year Range
0 0
Want to track CBIA and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Summary
CBIA closed Wednesday higher at $0, an increase of 0% from Tuesday's close, completing a monthly increase of 0% or $0. Over the past 12 months, CBIA stock lost -50%.
CBIA is not paying dividends to its shareholders.
The last earnings report, released on Mar 31, 2015, missed the consensus estimates by 0%. On average, the company has fell short of earnings expectations by -0.01%, based on the last three reports.
The stock of the company had never split.
The company's stock is traded on 1 different exchanges and in various currencies, with the primary listing on OTC PINK (USD).
CBIA Chart
Canopus Biopharma Inc. Dividends
CBIA is not paying dividends to its shareholders.
Canopus Biopharma Inc. Earnings
| 31 Mar 2015 Date | | - Cons. EPS | - EPS |
| 31 Dec 2014 Date | | - Cons. EPS | - EPS |
| 30 Sep 2014 Date | | - Cons. EPS | - EPS |
CBIA is not paying dividends to its shareholders.
| 31 Mar 2015 Date | | - Cons. EPS | - EPS |
| 31 Dec 2014 Date | | - Cons. EPS | - EPS |
| 30 Sep 2014 Date | | - Cons. EPS | - EPS |
Canopus Biopharma Inc. (CBIA) FAQ
What is the stock price today?
The current price is $0.00.
On which exchange is it traded?
Canopus Biopharma Inc. is listed on OTC PINK.
What is its stock symbol?
The ticker symbol is CBIA.
Does it pay dividends? What is the current yield?
Yes, It pays dividends and the current yield is 0%.
What is its market cap?
As of today, the market cap is 455.07K.
Has Canopus Biopharma Inc. ever had a stock split?
No, there has never been a stock split.
Canopus Biopharma Inc. Profile
| Shell Companies Industry | Financial Services Sector | Mr. Patrick T. Prendergast CEO | OTC PINK Exchange | 138034103 Cusip |
| US Country | - Employees | - Last Dividend | 16 Jul 2007 Last Split | - IPO Date |
Overview
Canopus BioPharma Incorporated is a distinguished player in the pharmaceutical research sector, advancing the development of pharmaceutical products and innovative assay methods. Dedicated to addressing the pressing needs of patients grappling with infectious diseases, cancer, and addiction, the company stands at the forefront of delivering groundbreaking solutions. Originally established in 1996 under the name Canopus Corporation, the organization embraced its current identity in 2007 to better reflect its deep commitment to the biopharmaceutical domain. Rooted in Santa Monica, California, Canopus BioPharma holds a legacy of pioneering contributions to medical science and health care.
Products and Services
- Antivirals: Canopus BioPharma has developed a line of antiviral medications designed to prevent and treat various viral infections. These products are the culmination of rigorous research, targeting viruses with precision and offering hope to those affected by infectious diseases.
- Radiation Protection Products: The company's radiation protection products provide a shield against harmful radiation exposure. This lineup is particularly relevant for individuals undergoing cancer treatment and professionals working in environments with elevated radiation levels, emphasizing Canopus BioPharma's commitment to oncology support and occupational health.
- Oncology Products: With a dedicated oncology range, Canopus BioPharma addresses the complexities of cancer treatment. These products target different forms of cancer, offering patients innovative therapeutic options that aim to improve quality of life and treatment outcomes.
- Bio-Barcode Assays: This distinctive offering involves bio-barcode assays, a sophisticated diagnostic technology that enhances the detection and quantification of proteins, nucleic acids, and other molecules. This technology stands as a testament to the company’s investment in cutting-edge research and its potential in transforming diagnostics.
- Camelidae Blood Products: Leveraging the unique antibodies found in camelid blood, Canopus BioPharma's products in this category offer promising applications in the treatment and research of infectious diseases, highlighting the innovative approaches the company takes in biopharmaceuticals.
- Neutraceuticals: The neutraceutical line encompasses a range of dietary supplements and functional foods designed to support overall health and complement traditional treatment regimens. These products demonstrate Canopus BioPharma's holistic approach to health, focusing on prevention and wellness alongside curing diseases.
Contact Information
Address: 233 Wilshire Boulevard
Phone: 353-627-8674
Website: https://www.blueheaven.cafe
2025 © Marketlog. All Rights Reserved.
